Business
Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2026 and raised its full year guidance for the year ending December 31, 2026. First Quarter 2026 Financial Highlights & Key Metrics Net sales of $27.6 million, up 57% compared to $17.6 million in the first quarter of 2025. Durable Medical Equipment (DME) channel
About this update from Beta Bionics, Inc.
[{"type":"image","alt":"Beta Bionics, Inc.","displaySize":"","headline":null,"caption":"Beta Bionics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":51,"url":"https://media.zenfs.com/en/globenewswire.com/0d351b90d528509a207c521057a3f8fc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cRiz2jc99sXdxdewERnMOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcx/https://media.zenfs.com/en/globenewswire.com/0d351b90d528509a207c521057a3f8fc","width":300,"height":51}},"lazy":false},{"type":"text","content":"IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2026 and raised its full year guidance for the year ending December 31, 2026.","length":314,"tagName":"p"},{"type":"text","content":"First Quarter 2026 Financial Highlights & Key Metrics","length":57,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net sales of $27.6 million, up 57% compared to $17.6 million in the first quarter of 2025.","length":90,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Durable Medical Equipment (DME) channel net sales of $16.9 million, up 22% compared to $13.8 million in the first quarter of 2025.","length":130,"tagName":"p"}]},{"val":[{"type":"text","content":"Pharmacy Benefit Plan (PBP) channel net sales of $10.7 million, up 181% compared to $3.8 million in the first quarter of 2025.","length":126,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":256,"olType":false}]},{"val":[{"type":"text","content":"Gross margin of 59.5%, up 864 basis points compared to 50.9% in the first quarter of 2025.","length":90,"tagName":"p"}]},{"val":[{"type":"text","content":"New patient starts declined by at least 10% but less than 20% sequentially versus the fourth quarter of 2025.","length":109,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"70% of new patient starts came from multiple daily injections (MDI).","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"High 30s percentage of new patient starts reimbursed through the PBP channel.","length":77,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":145,"olType":false}]},{"val":[{"type":"text","content":"Loss from operat...